Invasive fungal infections in pediatric patients: A review focusing on antifungal therapy

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 2, 2010, Pages 127-135

  Lass Flörl, Cornelia ^a  

^a Department of Hygiene Microbiology and Social Medicine ^*  (Austria)

Author keywords

antifungal treatment; Aspergillus infections; Candida infections; children; fungal infections; pediatric

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; MICAFUNGIN; VORICONAZOLE;

COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG RESPONSE; HUMAN; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LICENSING; MONOTHERAPY; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGE; ASPERGILLOSIS; CANDIDIASIS; CHILD; DOSE CALCULATION; INFANT; NEWBORN; PRESCHOOL CHILD;

AGE FACTORS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG DOSAGE CALCULATIONS; HUMANS; INFANT; INFANT, NEWBORN;

EID: 77954523110     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.128     Document Type: Review

References (62)

1. Gallin JI, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am. Clin. Climatol. Assoc. 118, 175-185 (2007).
2. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77, 345-354 (1998).
3. Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121, e1286-e294 (2008).
4. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in primary immunodeficiencies. Med. Mycol. 43(Suppl. 1), S247-S259 (2005). Review on fungal infections in primary immunodeficiencies, which are rare and usually first manifest during childhood.
5. Stergiopoulou T, Meletiadis J, Roilides E et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am. J. Clin. Pathol. 127, 349-355 (2007).
6. Herbrecht R, Denning DW, Patterson TF et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002).
7. Rubio PM, Sevilla J, González-Vicent M et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study. J. Pediatr. Hematol. Oncol. 31, 642-646 (2009).
8. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: A 10-year review. Pediatr. Radiol. 33, 453-460 (2003).
9. Leeflang MM, Debets-Ossenkopp YJ, Visser CE et al. Galactomannan detection for invasive aspergillosis 2 in immunocompromized patients. Cochrane Database Syst. Rev. CD007394 (2008). Recent review on the use of galactomannan detection forinvasive aspergillosis in immunocompromised patients.
10. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin. Infect. Dis. 41, 1242-1250 (2005).
11. Steinbach WJ, Addison RM, McLaughlin L et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J. 26, 558-564 (2007).
12. Hayden R, Pounds S, Knapp K et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr. Infect. Dis. J. 27, 815-819 (2009).
13. Thomas L, Baggen L, Chisholm J, Sharland M. Diagnosis and treatment of aspergillosis in children. Expert. Rev. Anti Infect. Ther. 7, 461-472 (2009). Recent update on diagnosis and treatment of aspergillosis in children.
14. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40, 1762-1769 (2005).
15. Hummel M, Spiess B, Roder J et al. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J. Med. Microbiol. 58(Pt 10), 1291-1297 (2009).
16. Walsh TJ, Anaissie EJ, Denning DW et al.; Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360 (2008).
17. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients -recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 88, 97-110 (2009).
18. Schwartz S, Thiel E. Cerebral aspergillosis: Tissue penetration is the key. Med. Mycol. 47(Suppl. 1), S387-S393 (2009).
19. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21, 240-248 (2002).
20. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36, 1122-1131 (2003).
21. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53, 935-944 (2009).
22. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46, 201-211 (2008).
23. Crandon JL, Banevicius MA, Fang AF et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 53, 5102-5107 (2009).
24. Kolve H, Ahlke E, Fegeler W, Ritter J, Jürgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J. Antimicrob. Chemother. 64, 383-387 (2009).
25. Moen MD, Lyseng-Willisamson KA, Scott LJ. Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69, 361-392 (2009).
26. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B ipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant. 36, 873-877 (2005).
27. Herbrecht R, Maertens J, Baila L et al. Caspofungin (C) as first-line therapy of invasive aspergillosis (IA) in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A study of the EORTC infectious diseases group ICAAC. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 25-28 October 2008 (Abstract M-2167).
28. Viscoli C, Herbrecht R, Akan H, Baila L et al.; Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 64, 1274-1281 (2009).
29. Groll AH, Attarbaschi A, Schuster FR et al. Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey. J. Antimicrob. Chemother. 57, 527-535 (2006).
30. Zaoutis T; for the Merck Caspofungin Protocol 043 Study Group. Prospective, multicenter study of caspofungin for treatment of documented fungal infections in pediatric patients. Presented at: 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 4-7 October 2007 (Presentation 12212).
31. Cesaro S, Giacchino M, Locatelli F et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect. Dis. 7, 28 (2007).
32. Flynn P, Seibel N, Arrieta AC. Treatment of invasive aspergillosis in pediatric patients with micafungin alone or in combination with other sistemic antifungal agents. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006 (Abstract M-891).
33. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
34. El-Nawawy AA, Abd El-Fattah MM, Metwally HA, Barakat SS, Hassan IA. One year study of bacterial and fungal nosocomial infections among patients in pediatric intensive care unit (PICU) in Alexandria. J. Trop. Pediatr. 52, 185-191 (2006).
35. Grisaru-Soen G, Paret G, Yahav D, Boyko V, Lerner-Geva L. Nosocomial infections in pediatric cardiovascular surgery patients: A 4-year survey. Pediatr. Crit. Care Med. 10, 202-206 (2009).
36. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin. Infect. Dis. 41, 1232-1239 (2005).
37. Blyth CC, Chen SC, Slavin MA et al.; Australian Candidemia Study. Not just little adults: Candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 123, 1360-1368 (2009).
38. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur. J. Pediatr. 166, 1099-1117 (2007).
39. Neu N, Malik M, Lunding A et al. Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr. Infect. Dis J. 28, 806-809 (2009).
40. Pappas PG, Kauffman CA, Andes D et al.; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 503-535 (2009).
41. Tirodker UH, Nataro JP, Smith S, LasCasas L, Fairchild KD. Detection of fungemia by polymerase chain reaction in critically ill neonates and children. J. Perinatol. 23, 117-122 (2003).
42. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) b-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41, 654-659 (2005).
43. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46(8), 2620-2629 (2008).
44. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115, 4745-4752 (2009).
45. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr. Infect. Dis. J. 28, 1061-1063 (2009).
46. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331, 1325-1330 (1994).
47. Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr. Infect. Dis. J. 15:1107-1112 (1996).
48. Wade KC, Benjamin DK Jr, Kaufman DA et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr. Infect. Dis. J. 28, 717-723 (2009).
49. Mora-Duarte J, Betts R, Rotstein C et al.; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347, 2020-2029 (2002).
50. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123, 877-884 (2009).
51. Kuse ER, Chetchotisakd P, da Cunha CA et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A Phase III randomised double-blind trial. Lancet 369, 1519-1527 (2007).
52. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007).
53. Queiroz-Telles F, Berezin E, Leverger G et al.; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27, 820-826 (2008).
54. Reboli AC, Rotstein C, Pappas PG et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356, 2472-2482 (2007).
55. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53, 935-944 (2009).
56. Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50, 632-638 (2009).
57. Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49, 4536-4545 (2005).
58. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49, 3317-3324 (2005).
59. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51, 3714-3719 (2005).
60. Ashouri N, Singh J, Arrieta A. Micafungin in pediatrics: When one size does not fit all. Expert Opin. Drug Metab. Toxicol. 4, 463-469 (2008).
61. Baddley JW, Pappas PG. Combination antifungal therapy for the treatment of invasive yeast and mold infections. Curr. Infect. Dis. Rep. 9, 448-456 (2007).
62. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39, 797-802 (2004).